Helicobacter pylori vaccination: Is there a path to protection?

World Journal of Gastroenterology

Volumn 20, Issue 34, 2014, Pages 11939-11949

  Anderl, Florian ^a   Gerhard, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Dendritic cells; Helicobacter pylori; Immune response; T cells; Vaccination

Indexed keywords

HELICOBACTER PYLORI VACCINE; VIRULENCE FACTOR; BACTERIAL VACCINE;

ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BACTERIAL COLONIZATION; DENDRITIC CELL; HELICOBACTER INFECTION; HUMAN; IMMUNE RESPONSE; NONHUMAN; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 TH2 BALANCE; TH17 CELL; VACCINATION; ANIMAL; CELLULAR IMMUNITY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOST PATHOGEN INTERACTION; HUMORAL IMMUNITY; IMMUNOLOGY; INNATE IMMUNITY; MICROBIOLOGY; PATHOGENICITY; TREATMENT OUTCOME; VIRULENCE;

ANIMALS; BACTERIAL VACCINES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, INNATE; TREATMENT OUTCOME; VACCINATION; VIRULENCE;

EID: 84909619308     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i34.11939     Document Type: Article

References (106)

1. Kabir S. The current status of Helicobacter pylori vaccines: a review. Helicobacter 2007; 12: 89-102 [PMID: 17309745]
2. Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, Rogers AB, Martin W, De Groot AS. HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 2011; 29: 2085-2091 [PMID: 21236233 DOI: 10.1016/j.vaccine.2010.12.130]
3. Sutton P, Chionh YT. Why can't we make an effective vaccine against Helicobacter pylori? Expert Rev Vaccines 2013; 12: 433-441 [PMID: 23560923 DOI: 10.1586/erv.13.20]
4. Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D, Herranz M, Saldinger PF, Corthésy-Theulaz I, Losonsky G, Nichols R, Simon J, Stolte M, Ackerman S, Monath TP, Blum AL. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999; 116: 804-812 [PMID: 10092302]
5. Hafsi N, Voland P, Schwendy S, Rad R, Reindl W, Gerhard M, Prinz C. Human dendritic cells respond to Helicobacter pylori, promoting NK cell and Th1-effector responses in vitro. J Immunol 2004; 173: 1249-1257 [PMID: 15240717]
6. Nagai S, Mimuro H, Yamada T, Baba Y, Moro K, Nochi T, Kiyono H, Suzuki T, Sasakawa C, Koyasu S. Role of Peyer's patches in the induction of Helicobacter pylori-induced gastritis. Proc Natl Acad Sci USA 2007; 104: 8971-8976 [PMID: 17502608]
7. Rad R, Ballhorn W, Voland P, Eisenächer K, Mages J, Rad L, Ferstl R, Lang R, Wagner H, Schmid RM, Bauer S, Prinz C, Kirschning CJ, Krug A. Extracellular and intracellular pattern recognition receptors cooperate in the recognition of Helicobacter pylori. Gastroenterology 2009; 136: 2247-2257 [PMID: 19272387 DOI: 10.1053/j.gastro.2009.02.066]
8. Torok AM, Bouton AH, Goldberg JB. Helicobacter pylori induces interleukin-8 secretion by Toll-like receptor 2- and Toll-like receptor 5-dependent and -independent pathways. Infect Immun 2005; 73: 1523-1531 [PMID: 15731050]
9. Mohammadi M, Czinn S, Redline R, Nedrud J. Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice. J Immunol 1996; 156: 4729-4738 [PMID: 8648119]
10. Rathbone BJ, Wyatt JI, Worsley BW, Shires SE, Trejdosiewicz LK, Heatley RV, Losowsky MS. Systemic and local antibody responses to gastric Campylobacter pyloridis in non-ulcer dyspepsia. Gut 1986; 27: 642-647 [PMID: 3721286]
11. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30: 1-22 [PMID: 22136168 DOI: 10.1146/annurev-immunol-100311-102839]
12. Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007; 204: 1757-1764 [PMID: 17620361]
13. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007; 204: 1775-1785 [PMID: 17620362]
14. Niess JH, Brand S, Gu X, Landsman L, Jung S, McCormick BA, Vyas JM, Boes M, Ploegh HL, Fox JG, Littman DR, Reinecker HC. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005; 307: 254-258 [PMID: 15653504]
15. Khamri W, Walker MM, Clark P, Atherton JC, Thursz MR, Bamford KB, Lechler RI, Lombardi G. Helicobacter pylori stimulates dendritic cells to induce interleukin-17 expression from CD4+ T lymphocytes. Infect Immun 2010; 78: 845-853 [PMID: 19917709 DOI: 10.1128/IAI.00524-09]
16. Kao JY, Pierzchala A, Rathinavelu S, Zavros Y, Tessier A, Merchant JL. Somatostatin inhibits dendritic cell responsiveness to Helicobacter pylori. Regul Pept 2006; 134: 23-29 [PMID: 16375983]
17. Zhang M, Liu M, Luther J, Kao JY. Helicobacter pylori directs tolerogenic programming of dendritic cells. Gut Microbes 2010; 1: 325-329 [PMID: 21327041]
18. Oertli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, Reuter S, Maxeiner J, Hansson M, Taube C, Quiding-Järbrink M, Müller A. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest 2012; 122: 1082-1096 [PMID: 22307326 DOI: 10.1172/JCI61029]
19. Hitzler I, Oertli M, Becher B, Agger EM, Müller A. Dendritic cells prevent rather than promote immunity conferred by a helicobacter vaccine using a mycobacterial adjuvant. Gastroenterology 2011; 141: 186-96, 196.e1 [PMID: 21569773 DOI: 10.1053/j.gastro.2011.04.009]
20. Wyatt JI, Rathbone BJ, Heatley RV. Local immune response to gastric Campylobacter in non-ulcer dyspepsia. J Clin Pathol 1986; 39: 863-870 [PMID: 3528230]
21. Formichella L, Romberg L, Bolz C, Vieth M, Geppert M, Göttner G, Nölting C, Walter D, Schepp W, Schneider A, Ulm K, Wolf P, Busch DH, Soutschek E, Gerhard M. A novel line immunoassay based on recombinant virulence factors enables highly specific and sensitive serologic diagnosis of Helicobacter pylori infection. Clin Vaccine Immunol 2013; 20: 1703-1710 [PMID: 24006137 DOI: 10.1128/CVI.00433-13]
22. Akhiani AA, Schön K, Franzén LE, Pappo J, Lycke N. Helicobacter pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J Immunol 2004; 172: 5024-5033 [PMID: 15067084]
23. Bussiere FI, Chaturvedi R, Asim M, Hoek KL, Cheng Y, Gainor J, Scholz A, Khan WN, Wilson KT. Low multiplicity of infection of Helicobacter pylori suppresses apoptosis of B lymphocytes. Cancer Res 2006; 66: 6834-6842 [PMID: 16818661]
24. Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin R, Lee CK, Kleanthous H, Monath TP. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 1998; 188: 2277-2288 [PMID: 9858514]
25. Michetti M, Kelly CP, Kraehenbuhl JP, Bouzourene H, Michetti P. Gastric mucosal alpha(4)beta(7)-integrin-positive CD4 T lymphocytes and immune protection against helicobacter infection in mice. Gastroenterology 2000; 119: 109-118 [PMID: 10889160]
26. Fan XJ, Chua A, Shahi CN, McDevitt J, Keeling PW, Kelleher D. Gastric T lymphocyte responses to Helicobacter pylori in patients with H pylori colonisation. Gut 1994; 35: 1379-1384 [PMID: 7959191]
27. Eaton KA, Mefford M, Thevenot T. The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J Immunol 2001; 166: 7456-7461 [PMID: 11390498]
28. Smythies LE, Waites KB, Lindsey JR, Harris PR, Ghiara P, Smith PD. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J Immunol 2000; 165: 1022-1029 [PMID: 10878379]
29. D'Elios MM, Manghetti M, De Carli M, Costa F, Baldari CT, Burroni D, Telford JL, Romagnani S, Del Prete G. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 1997; 158: 962-967 [PMID: 8993017]
30. Sommer F, Faller G, Konturek P, Kirchner T, Hahn EG, Zeus J, Röllinghoff M, Lohoff M. Antrum- and corpus mucosa-infiltrating CD4(+) lymphocytes in Helicobacter pylori gastritis display a Th1 phenotype. Infect Immun 1998; 66: 5543-5546 [PMID: 9784570]
31. Taylor JM, Ziman ME, Fong J, Solnick JV, Vajdy M. Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations. Infect Immun 2007; 75: 3462-3469 [PMID: 17502399]
32. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132 [PMID: 16200070]
33. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141 [PMID: 16200068]
34. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt R. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-957 [PMID: 17676044]
35. Ivanov II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Finlay BB, Littman DR. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008; 4: 337-349 [PMID: 18854238 DOI: 10.1016/j.chom.2008.09.009]
36. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126: 1121-1133 [PMID: 16990136]
37. Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, Winter SE, Godinez I, Sankaran S, Paixao TA, Gordon MA, Kolls JK, Dandekar S, Bäumler AJ. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 2008; 14: 421-428 [PMID: 18376406 DOI: 10.1038/nm1743]
38. Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, Ho AW, Hai JH, Yu JJ, Jung JW, Filler SG, Masso-Welch P, Edgerton M, Gaffen SL. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009; 206: 299-311 [PMID: 19204111 DOI: 10.1084/jem.20081463]
39. Chung DR, Kasper DL, Panzo RJ, Chitnis T, Grusby MJ, Sayegh MH, Tzianabos AO. CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol 2003; 170: 1958-1963 [PMID: 12574364]
40. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004; 190: 624-631 [PMID: 15243941]
41. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-2279 [PMID: 16982811]
42. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240 [PMID: 15657292]
43. Veldhoen M, Hocking RJ, Flavell RA, Stockinger B. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol 2006; 7: 1151-1156 [PMID: 16998492]
44. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238 [PMID: 16648838]
45. Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Semin Immunol 2007; 19: 377-382 [PMID: 18054248]
46. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, Oukka M, Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448: 484-487 [PMID: 17581588]
47. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179-189 [PMID: 16473830]
48. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441: 231-234 [PMID: 16648837]
49. Caruso R, Pallone F, Monteleone G. Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. World J Gastroenterol 2007; 13: 5547-5551 [PMID: 17948927]
50. Otani K, Watanabe T, Tanigawa T, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Arakawa T. Anti-inflammatory effects of IL-17A on Helicobacter pylori-induced gastritis. Biochem Biophys Res Commun 2009; 382: 252-258 [PMID: 19249291 DOI: 10.1016/j.bbrc.2009.02.107]
51. Shiomi S, Toriie A, Imamura S, Konishi H, Mitsufuji S, Iwakura Y, Yamaoka Y, Ota H, Yamamoto T, Imanishi J, Kita M. IL-17 is involved in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Helicobacter 2008; 13: 518-524 [PMID: 19166417 DOI: 10.1111/j.1523-5378.2008.00629.x]
52. Algood HM, Allen SS, Washington MK, Peek RM, Miller GG, Cover TL. Regulation of gastric B cell recruitment is dependent on IL-17 receptor A signaling in a model of chronic bacterial infection. J Immunol 2009; 183: 5837-5846 [PMID: 19812196 DOI: 10.4049/jimmunol.0901206]
53. DeLyria ES, Redline RW, Blanchard TG. Vaccination of mice against H pylori induces a strong Th-17 response and immunity that is neutrophil dependent. Gastroenterology 2009; 136: 247-256 [PMID: 18948106 DOI: 10.1053/j.gastro.2008.09.017]
54. Velin D, Favre L, Bernasconi E, Bachmann D, Pythoud C, Saiji E, Bouzourene H, Michetti P. Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 2009; 136: 2237-2246.e1 [PMID: 19272385 DOI: 10.1053/j.gastro.2009.02.077]
55. Kandulski A, Wex T, Kuester D, Peitz U, Gebert I, Roessner A, Malfertheiner P. Naturally occurring regulatory T cells (CD4+, CD25high, FOXP3+) in the antrum and cardia are associated with higher H. pylori colonization and increased gene expression of TGF-beta1. Helicobacter 2008; 13: 295-303 [PMID: 18665940 DOI: 10.1111/j.1523-5378.2008.00612.x]
56. Rad R, Brenner L, Bauer S, Schwendy S, Layland L, da Costa CP, Reindl W, Dossumbekova A, Friedrich M, Saur D, Wagner H, Schmid RM, Prinz C. CD25+/Foxp3+ T cells regulate gastric inflammation and Helicobacter pylori colonization in vivo. Gastroenterology 2006; 131: 525-537 [PMID: 16890606]
57. Lundgren A, Strömberg E, Sjöling A, Lindholm C, Enarsson K, Edebo A, Johnsson E, Suri-Payer E, Larsson P, Rudin A, Svennerholm AM, Lundin BS. Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun 2005; 73: 523-531 [PMID: 15618192]
58. Enarsson K, Lundgren A, Kindlund B, Hermansson M, Roncador G, Banham AH, Lundin BS, Quiding-Järbrink M. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin Immunol 2006; 121: 358-368 [PMID: 16934529]
59. Lee CW, Rao VP, Rogers AB, Ge Z, Erdman SE, Whary MT, Fox JG. Wild-type and interleukin-10-deficient regulatory T cells reduce effector T-cell-mediated gastroduodenitis in Rag2-/- mice, but only wild-type regulatory T cells suppress Helicobacter pylori gastritis. Infect Immun 2007; 75: 2699-2707 [PMID: 17353283]
60. Arnold IC, Lee JY, Amieva MR, Roers A, Flavell RA, Sparwasser T, Müller A. Tolerance rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia. Gastroenterology 2011; 140: 199-209 [PMID: 20600031 DOI: 10.1053/j.gastro.2010.06.047]
61. Vajdy M, Singh M, Ugozzoli M, Briones M, Soenawan E, Cuadra L, Kazzaz J, Ruggiero P, Peppoloni S, Norelli F, del Giudice G, O'Hagan D. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 2003; 110: 86-94 [PMID: 12941145]
62. Nyström J, Svennerholm AM. Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses. Vaccine 2007; 25: 2591-2598 [PMID: 17239498]
63. Sanchez V, Gimenez S, Haensler J, Geoffroy C, Rokbi B, Seguin D, Lissolo L, Harris B, Rizvi F, Kleanthous H, Monath T, Cadoz M, Guy B. Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones. FEMS Immunol Med Microbiol 2001; 30: 157-165 [PMID: 11267850]
64. Li Y, Jiang Y, Xi Y, Zhang L, Luo J, He D, Zeng S, Ning Y. Identification and characterization of H-2d restricted CD4+ T cell epitopes on Lpp20 of Helicobacter pylori. BMC Immunol 2012; 13: 68 [PMID: 23234363 DOI: 10.1186/1471-2172-13-68]
65. Keenan J, Oliaro J, Domigan N, Potter H, Aitken G, Allardyce R, Roake J. Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate. Infect Immun 2000; 68: 3337-3343 [PMID: 10816482]
66. O'Riordan AA, Morales VA, Mulligan L, Faheem N, Windle HJ, Kelleher DP. Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine. Vaccine 2012; 30: 3876-3884 [PMID: 22512976 DOI: 10.1016/j.vaccine.2012.04.002]
67. Stent A, Every AL, Ng GZ, Chionh YT, Ong LS, Edwards SJ, Sutton P. Helicobacter pylori thiolperoxidase as a protective antigen in single- and multi-component vaccines. Vaccine 2012; 30: 7214-7220 [PMID: 23084846 DOI: 10.1016/j.vaccine.2012.10.022]
68. Huang X, Xu B, Duan G, Song C. The rOmp22-HpaA fusion protein confers protective immunity against helicobacter pylori in mice. Curr Microbiol 2013; 67: 487-492 [PMID: 23715666 DOI: 10.1007/s00284-013-0390-x]
69. Corthésy-Theulaz IE, Hopkins S, Bachmann D, Saldinger PF, Porta N, Haas R, Zheng-Xin Y, Meyer T, Bouzourène H, Blum AL, Kraehenbuhl JP. Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun 1998; 66: 581-586 [PMID: 9453612]
70. Gómez-Duarte OG, Lucas B, Yan ZX, Panthel K, Haas R, Meyer TF. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 1998; 16: 460-471 [PMID: 9491500]
71. Novak MJ, Smythies LE, McPherson SA, Smith PD, Morrow CD. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immune response. Vaccine 1999; 17: 2384-2391 [PMID: 10392620]
72. Chen J, Lin M, Li N, Lin L, She F. Therapeutic vaccination with Salmonella-delivered codon-optimized outer inflammatory protein DNA vaccine enhances protection in Helicobacter pylori infected mice. Vaccine 2012; 30: 5310-5315 [PMID: 22749593 DOI: 10.1016/j.vaccine.2012.06.052]
73. Liu KY, Shi Y, Luo P, Yu S, Chen L, Zhao Z, Mao XH, Guo G, Wu C, Zou QM. Therapeutic efficacy of oral immunization with attenuated Salmonella typhimurium expressing Helicobacter pylori CagA, VacA and UreB fusion proteins in mice model. Vaccine 2011; 29: 6679-6685 [PMID: 21745524 DOI: 10.1016/j.vaccine.2011.06.099]
74. Li HX, Mao XH, Shi Y, Ma Y, Wu YN, Zhang WJ, Luo P, Yu S, Zhou WY, Guo Y, Wu C, Guo G, Zou QM. Screening and identification of a novel B-cell neutralizing epitope from Helicobacter pylori UreB. Vaccine 2008; 26: 6945-6949 [PMID: 18948159 DOI: 10.1016/j.vaccine.2009.05.009]
75. Li HB, Zhang JY, He YF, Chen L, Li B, Liu KY, Yang WC, Zhao Z, Zou QM, Wu C. Systemic immunization with an epitope-based vaccine elicits a Th1-biased response and provides protection against Helicobacter pylori in mice. Vaccine 2012; 31: 120-126 [PMID: 23137845 DOI: 10.1016/j.vaccine.2012.10.091]
76. Moise L, McMurry JA, Pappo J, Lee DS, Moss SF, Martin WD, De Groot AS. Identification of genome-derived vaccine candidates conserved between human and mouse-adapted strains of H. pylori. Hum Vaccin 2008; 4: 219-223 [PMID: 18376134]
77. Lee SK, Stack A, Katzowitsch E, Aizawa SI, Suerbaum S, Josenhans C. Helicobacter pylori flagellins have very low intrinsic activity to stimulate human gastric epithelial cells via TLR5. Microbes Infect 2003; 5: 1345-1356 [PMID: 14670447]
78. Gewirtz AT, Yu Y, Krishna US, Israel DA, Lyons SL, Peek RM. Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 2004; 189: 1914-1920 [PMID: 15122529]
79. Mori J, Vranac T, Smrekar B, Cernilec M, Serbec VČ, Horvat S, Ihan A, Benčina M, Jerala R. Chimeric flagellin as the self-adjuvanting antigen for the activation of immune response against Helicobacter pylori. Vaccine 2012; 30: 5856-5863 [PMID: 22819990 DOI: 10.1016/j.vaccine.2012.07.011]
80. Taylor JM, Ziman ME, Huff JL, Moroski NM, Vajdy M, Solnick JV. Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice. Vaccine 2006; 24: 4987-4994 [PMID: 16621176]
81. Sjökvist Ottsjö L, Flach CF, Clements J, Holmgren J, Raghavan S. A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun 2013; 81: 1532-1540 [PMID: 23439305 DOI: 10.1128/IAI.01407-12]
82. Agren LC, Ekman L, Löwenadler B, Lycke NY. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. J Immunol 1997; 158: 3936-3946 [PMID: 9103464]
83. Eriksson AM, Schön KM, Lycke NY. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 2004; 173: 3310-3319 [PMID: 15322194]
84. Sundling C, Schön K, Mörner A, Forsell MN, Wyatt RT, Thorstensson R, Karlsson Hedestam GB, Lycke NY. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J Gen Virol 2008; 89: 2954-2964 [PMID: 19008380 DOI: 10.1099/vir.0.2008/005470-0]
85. Akhiani AA, Stensson A, Schön K, Lycke N. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization. Scand J Immunol 2006; 63: 97-105 [PMID: 16476008]
86. Kreiss C, Buclin T, Cosma M, Corthésy-Theulaz I, Michetti P. Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. Lancet 1996; 347: 1630-1631 [PMID: 8667902]
87. Banerjee S, Medina-Fatimi A, Nichols R, Tendler D, Michetti M, Simon J, Kelly CP, Monath TP, Michetti P. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002; 51: 634-640 [PMID: 12377799]
88. Sougioultzis S, Lee CK, Alsahli M, Banerjee S, Cadoz M, Schrader R, Guy B, Bedford P, Monath TP, Kelly CP, Michetti P. Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 2002; 21: 194-201 [PMID: 12450694]
89. Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001; 69: 3581-3590 [PMID: 11349017]
90. Losonsky GA, Kotloff KL, Walker RI. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H pylori seronegative individuals. Vaccine 2003; 21: 562-565 [PMID: 12531656]
91. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999; 18: 449-459 [PMID: 10519934]
92. Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun 2000; 68: 2135-2141 [PMID: 10722611]
93. Bumann D, Metzger WG, Mansouri E, Palme O, Wendland M, Hurwitz R, Haas G, Aebischer T, von Specht BU, Meyer TF. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2001; 20: 845-852 [PMID: 11738748]
94. Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, Novicki D, Norelli F, Contorni M, Peppoloni S, Berti D, Tornese D, Ganju J, Palla E, Rappuoli R, Scharschmidt BF, Del Giudice G. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008; 135: 787-795 [PMID: 18619971 DOI: 10.1053/j.gastro.2008.05.054]
95. Malfertheiner P, Selgrad M, Wex T, Bornschein J, Palla E, Del Giudice G, Graham D, Heaton PM. Efficacy of an investigational recombinant antigen based vaccine against a CagA H. pylori infectious challenge in healthy volunteers (abstract). Gastroenterology 2012; 142: S-184.
96. Moodley Y, Linz B, Bond RP, Nieuwoudt M, Soodyall H, Schlebusch CM, Bernhöft S, Hale J, Suerbaum S, Mugisha L, van der Merwe SW, Achtman M. Age of the association between Helicobacter pylori and man. PLoS Pathog 2012; 8: e1002693 [PMID: 22589724 DOI: 10.1371/journal.ppat.1002693]
97. Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis 2008; 198: 553-560 [PMID: 18598192 DOI: 10.1086/590158]
98. Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, Taube C, Müller A. Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest 2011; 121: 3088-3093 [PMID: 21737881 DOI: 10.1172/JCI45041]
99. Barrozo RM, Cooke CL, Hansen LM, Lam AM, Gaddy JA, Johnson EM, Cariaga TA, Suarez G, Peek RM, Cover TL, Solnick JV. Functional plasticity in the type IV secretion system of Helicobacter pylori. PLoS Pathog 2013; 9: e1003189 [PMID: 23468628 DOI: 10.1371/journal.ppat.1003189]
100. Fischer W, Prassl S, Haas R. Virulence mechanisms and persistence strategies of the human gastric pathogen Helicobacter pylori. Curr Top Microbiol Immunol 2009; 337: 129-171 [PMID: 19812982 DOI: 10.1007/978-3-642-01846-6-5]
101. Guo L, Liu K, Xu G, Li X, Tu J, Tang F, Xing Y, Xi T. Prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA against Helicobacter pylori infection in a BALB/c mice model. Appl Microbiol Biotechnol 2012; 95: 1437-1444 [PMID: 22569640 DOI: 10.1007/s00253-012-4122-0]
102. Coccia EM, Remoli ME, Di Giacinto C, Del Zotto B, Giacomini E, Monteleone G, Boirivant M. Cholera toxin subunit B inhibits IL-12 and IFN-{gamma} production and signaling in experimental colitis and Crohn's disease. Gut 2005; 54: 1558-1564 [PMID: 16105891]
103. la Sala A, He J, Laricchia-Robbio L, Gorini S, Iwasaki A, Braun M, Yap GS, Sher A, Ozato K, Kelsall B. Cholera toxin inhibits IL-12 production and CD8alpha+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function. J Exp Med 2009; 206: 1227-1235 [PMID: 19487420 DOI: 10.1084/jem.20080912]
104. Norton EB, Lawson LB, Freytag LC, Clements JD. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol 2011; 18: 546-551 [PMID: 21288994 DOI: 10.1128/CVI.00538-10]
105. Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker R, Svennerholm AM. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant. Vaccine 2013; 31: 2457-2464 [PMID: 23541621 DOI: 10.1016/j.vaccine.2013.03.027]
106. Svennerholm AM, Lundgren A. Recent progress toward an enterotoxigenic Escherichia coli vaccine. Expert Rev Vaccines 2012; 11: 495-507 [PMID: 22551034 DOI: 10.1586/erv.12.12]